The Paris court ruled on Wednesday January 5 that Sanofi had "
committed a fault by failing to fulfill its obligation of vigilance and its obligation to inform
" concerning the risks of its drug Depakine for the fetus if taken during pregnancy.
Read also Depakine: the drug agency indicted for "manslaughter"
He also considered "
admissible
" the group action presented by the association of victims of Dépakine against the laboratory, paving the way for a first judicial in the field of health.
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/6GEKDOLV2NGJ7PQMJUEXGFLG6Y.JPG)